Peregrine to Report Financial Results for the Quarter and Fiscal Year Ended April 30, 2016 After Market Close on July 14, 201...
July 07 2016 - 4:05PM
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a
biopharmaceutical company committed to improving patient lives by
delivering high quality biological products through its contract
development and manufacturing organization (CDMO) services and by
advancing its novel R&D pipeline, today announced that it will
report financial results for the quarter and fiscal year (FY)
ended April 30, 2016 on July 14, 2016 after market
close and will host a conference call and webcast at 1:30 PM
Pacific Time (4:30 PM Eastern Time). Peregrine's senior management
will discuss financial results for the quarter and FY
ended April 30, 2016 and review recent corporate
developments.
To listen to the live webcast, or access the
archived webcast, please visit:
http://ir.peregrineinc.com/events.cfm.
To listen to the conference call, please dial
(877) 312-5443 or (253) 237-1126 and request the Peregrine
Pharmaceuticals call.
About Peregrine Pharmaceuticals,
Inc.
Peregrine Pharmaceuticals, Inc. is a
biopharmaceutical company committed to improving the lives of
patients by delivering high quality pharmaceutical products through
its contract development and manufacturing organization (CDMO)
services and through advancing and licensing its investigational
immunotherapy and related products. Peregrine's in-house CDMO
services, including cGMP manufacturing and development
capabilities, are provided through its wholly-owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. The company is also working to evaluate its lead
immunotherapy candidate, bavituximab, in combination with immune
stimulating therapies for the treatment of various cancers.
For more information, please visit www.peregrineinc.com.
Contacts:
Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024